STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Sponsor
Canadian Cancer Trials Group
Study ID
NCT06880523
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Key Dates

Start date
Oct 21, 2025
Status verified
Oct 2025
Primary completion
Jan 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
140 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: STRIDE (durvalumab + tremelimumab)
  • Experimental: STRIDE (durvalumab + tremelimumab) + Lenvatinib

Primary Outcome Measure

Progression-free Survival using RECIST 1.1 [ Time Frame: 32 months ]

Central Contacts

Related Studies